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Oxidized Low Density Lipoprotein Suppresses Expression of
Inducible Cyclooxygenase in Human Macrophages
Sonia Eligini, Susanna Colli, Federica Basso, Luigi Sironi, Elena Tremoli
Abstract—Atherogenesis involves several aspects of chronic inflammation and wound healing. Indeed, the atheroma is
considered a special case of tissue response to injury. Injurious stimuli may include lipoproteins trapped within lesions
where protein and lipid moieties have undergone chemical modifications. We have studied the effect of oxidized low
density lipoproteins (ox-LDL) on inducible cyclooxygenase (Cox-2) in human monocyte–derived macrophages exposed
to bacterial lipopolysaccharide (LPS). Levels of both Cox-2 and constitutive cyclooxygenase (Cox-1) were assessed
using Western blot analysis. Prior incubation of macrophages with ox-LDL resulted in a strong inhibition of Cox-2
induced by LPS, without effect on Cox-1. The inhibitory effect was dependent on ox-LDL concentration and its onset
was early in time (already detectable 1 hour after macrophage exposure to ox-LDL). Native LDL, and other forms of
modified LDL, were without effect. The inhibition was dependent on endocytosis of ox-LDL and could be reproduced
using the lipid extract from ox-LDL. Lysophosphatidylcholine, 7b-hydroxycholesterol, and 7-oxocholesterol failed to
mimic the inhibition, but oxidized arachidonic acid–containing phospholipids, produced by autoxidation of 1-palmitoyl-
2-arachidonoyl-sn-glycero-3-phosphocholine, markedly inhibited Cox-2. The observation that ox-LDL downregulates
Cox-2 in human macrophages may explain the fact that, within atheromata, the transformation of macrophages into
foam cells results in attenuation of the inflammatory response, thus contributing to progression of atherogenesis.
(Arterioscler Thromb Vasc Biol. 1999;19:1719-1725.)
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Monocyte-derived macrophages play a prominent role inthe formation and progression of the atherosclerotic
plaque, particularly after their transformation into foam cells.1,2
In this scenario an important feature is the oxidized LDL
(ox-LDL) present in the atherosclerotic lesion.3 These lesion
LDLs have many of the same physical and chemical properties
as LDLs that have been oxidatively modified in vitro.3
The interaction of ox-LDL with macrophages is generally
believed to be an early step in the process of their transfor-
mation into the foam cells composing the fatty streak, a
primary histologic aspect of incipient atherosclerosis. Indeed,
the accumulation of lipid within macrophages appears to be
mediated by their selective recognition and uptake of ox-
LDL.4 In addition to being internalized by macrophages,
ox-LDL affects many aspects of macrophage behavior in
ways that appear to promote atherogenesis.5–8
Macrophages, when activated by inflammatory stimuli,
synthesize and secrete various mediators (ie, proteases, active
oxygen species, cytokines, prothrombotic substances, and
eicosanoids), which cause the clinical manifestations and
acute clinical complications of atherosclerosis.9
The eicosanoids derived from the metabolism of arachid-
onate have been extensively investigated because several
studies have focused on their close relation to atherogene-
sis.10–17 In macrophages, as well as in other cell types,
arachidonate metabolites are synthesized by the cyclooxygen-
ase enzyme, which is present in 2 isoforms. Cyclooxygen-
ase-1 (Cox-1) is constitutively expressed, whereas the more
recently described isoform, the mitogen-inducible cyclooxy-
genase (Cox-2), is usually absent from resting cells and is
selectively expressed by macrophages exposed to lipopoly-
saccharide (LPS).18 Distinct pools of arachidonic acid are
available to Cox enzymes: 1 pool used by Cox-1 for physi-
ological functions; the other released on cell activation and
used as substrate by Cox-2.19 In macrophages, Cox-2 expres-
sion appears to be mediated through both mitogen-activated
protein kinase and nuclear factor-kB (NF-kB) signaling
pathways.20
In mouse macrophages exposed to atherogenic lipoproteins
and subsequently stimulated with various inflammatory stim-
uli a decreased production of eicosanoids such as prostacyclin
and prostaglandin E2 has been described, which indicates that
the uptake of modified lipoproteins negatively affects some
aspects of the proinflammatory potential of macrophages.21,22
The link between the oxidative modification of LDL and an
impairment of macrophage inflammatory response has been
strengthened by data from Hamilton et al,23,24 who elegantly
demonstrated that ox-LDL suppresses several inducible genes
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necessary for the inflammatory response of macrophages.
These data suggest a potent, direct connection between the
oxidative modification of LDL and the failure of macro-
phages to correctly resolve the tissue damage within athero-
genic lesions, which then leads to a chronic inflammatory
status.
In this study we investigated the effect of native and
modified LDL on Cox-2 enzyme in human monocyte–
derived macrophages in culture. Our data show that ox-LDL
inhibits Cox-2 enzyme and that this inhibition is caused by a
marked attenuation of Cox-2 mRNA levels.
Methods
Reagents
Cell culture medium and reagents were purchased from BioWhit-
taker. Lipopolysaccharide (Escherichia coli 0114:B4) was from
Difco Labs. Benzamidine hydrochloride, leupeptin hemisulphate,
soybean trypsin inhibitor, sodium orthovanadate, fucoidin, cytocha-
lasin B, chloroquine, phosphatidylcholine (PC), lysophosphatidyl-
choline (lysoPC) from egg yolk, 7-oxocholesterol, 7b-hydroxycho-
lesterol, 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine
(PAPC), monoclonal antibody anti-b-actin, BSA (fatty acid–free and
low in endotoxin), and Fat Red 7B were from Sigma Chemical Co.
EDTA and NaF were from Carlo Erba. Electrophoresis reagents
were from Pharmacia Biotech. TRIzol Reagent was from Life
Technologies. Peroxidase-conjugated anti-mouse IgG antibody was
from Jackson ImmunoResearch. Monoclonal antibodies against
Cox-2 (mAb 29) and Cox-1 (mAb 10 and 11) were kindly donated
by Dr J. Maclouf (U 348, INSERM, Paris).
Isolation of LDL and Phospholipids and
Their Modifications
LDLs were isolated by sequential preparative ultracentrifugation of
plasma from normolipidemic donors (containing 100 U/mL aprotinin
and 10 mmol/L phenylmethylsulfonylfluoride) in a Beckman
SW50Ti rotor at d51.024 to 1.050 g/mL.25 LDLs were extensively
dialyzed against phosphate buffer (1.5 mmol/L NaH2PO4 and
3.5 mmol/L Na2HPO4, pH 7.5) at 4°C. Acetyl-LDL was obtained by
diluting LDL with an equal volume of saturated sodium acetate
followed by treatment with acetic anhydride.26 Ox-LDL was ob-
tained by dialysis against phosphate buffer supplemented with
10 mmol/L CuSO4 at 4°C for 48 hours. Malondialdehyde-modified
LDL (MDA-LDL) was prepared by incubating LDL for 3 hours at
37°C with 0.5 mol/L MDA at a constant ratio of 100 mL/mg of LDL.
MDA was freshly generated from malonaldehyde bis(dimethylac-
etal) by acid hydrolysis at 37°C for 10 minutes.27 The extent of LDL
modification was assessed by electrophoretic mobility using 1%
agarose. Protein contents of native and modified LDL were quanti-
fied using the Lowry method.28 Native and modified LDL were
sterilized by passage through 0.22 mm filters, stored in sterile tubes
at 4°C, and used within 1 month. All preparations were tested for
LPS contamination using the Limulus test. Only those preparations
containing LPS levels ,0.1 ng/mg protein were used for the study.
Oxidized PAPC was obtained by transferring 1 mg PAPC in 100 mL
of chloroform to a clean 163125 mm glass test tube and evaporating
the solvent under a stream of nitrogen. The lipid residue was allowed
to autoxidize on exposure to air for 48 hours. Oxidized PAPC
(ox-PAPC) was reduced by resuspending 250 mg of lipid residue in
0.5 mL of a 0.1 mol/L borate buffer (pH 8.0) and adding 10 mg of
sodium borohydride. The lipids were instantly reduced.29
Cell Culture and Incubation
Venous blood from healthy donors was anticoagulated with 3.8%
sodium citrate, and mononuclear cells were then separated using
Ficoll-Paque solution (Pharmacia Fine Chemicals) at 450g for 20
minutes. Mononuclear cells were washed with PBS containing
EDTA (5 mmol/L) and suspended (33106/mL) in RPMI 1640
supplemented with 2 mmol/L glutamine, 0.5% penicillin-
streptomycin-fungizone, and 10% human heat-inactivated AB se-
rum. Monocytes were isolated from lymphocytes by adherence (2
hours at 37°C, 5% CO2, humid atmosphere) to 6-well plates. Cell
preparations were .90% monocytes, as determined by nonspecific
esterase staining. Macrophages were obtained by culturing mono-
cytes for 7 days at 37°C in a 5% CO2 humid atmosphere in M-199
supplemented with 2 mmol/L glutamine, 0.5% antibiotics, and 10%
human heat-inactivated AB serum; macrophages were identified by
the presence of the CD68Ag, which was detected using a specific
monoclonal mouse anti-human macrophage antibody (Dako). The
endotoxin content of all culture materials and reagents was measured
with the Limulus amebocyte lysate assay (BioWhittaker) and only
those containing ,3 pg/mL of endotoxin were used.
Macrophages were first incubated in serum-free medium contain-
ing 0.2% fatty acid–free BSA for times ranging from 1 to 24 hours
with native or modified LDL. Medium was then removed and
macrophages were exposed for an additional 4 hours to fresh
medium containing LPS (1 mg/mL). Incubation times and LPS
concentration were selected after preliminary experiments. Cell
viability was .95% as determined by Neutral Red assay. To
evaluate cyclooxygenase activity, cells were washed with Hanks’
buffer (pH 7.4) containing 1 mg/mL BSA and incubated with the
same buffer containing 10 mmol/L sodium arachidonate. After 30
minutes, supernatants were harvested and TxB2 levels were quanti-
fied using enzyme immunoassay (EIA).
Western Blot Analysis
After incubation, macrophages were lysed in buffer (20 mmol/L
Tris-HCl [pH 6.8], 4% SDS, 20% glycerol, 1 mmol/L EDTA,
1 mmol/L benzamidine hydrochloride, 1 mg/mL leupeptin, 10
mg/mL soybean trypsin inhibitor, 1 mmol/L NaF, and 1 mmol/L
orthovanadate). Protein content was quantified using the micro-
bicinchoninic acid assay30; 40 mg of protein (reducing conditions)
was used for analysis. SDS-PAGE analysis was performed using 7%
and 3% acrylamide for the separating gel and stacking gel, respec-
tively. Proteins were transferred onto nitrocellulose membranes
(Sartorius AG) with a semidry transfer unit (Hoefer Scientific
Instruments).31 Transfer was performed in a 25 mmol/L Tris,
192 mmol/L glycine buffer (pH 8.3; containing 0.01% SDS and 15%
methanol), for 2 hours at 200 mA. Blots, stained with 0.4% Ponceau
Red in 0.3% trichloroacetic acid to visualize proteins, were saturated
for 2 hours at room temperature with 5% fat-free dry milk in
Tris-buffered saline (50 mmol/L Tris-HCl [pH 7.5], 250 mmol/L
NaCl, and 0.1% Tween 20) and incubated with Cox-2 (1/10 000) or
Cox-1 (5 mg/mL) mAbs for 1 hour at room temperature. Monoclonal
antibody directed against b-actin was used as internal standard for
control of protein load. Blots were incubated with donkey anti-
mouse IgG conjugated with peroxidase at 1/5000 (0.1 mL/cm2 for 1
hour at room temperature. ECL (Amersham) substrates were used
according to the manufacturer’s instructions to reveal positive bands.
Bands were visualized after exposure to Hyperfilm ECL
(Amersham).
Detection of Cox-2 mRNA by RT-PCR
Total cellular RNA was extracted from macrophages with TRIzol
Reagent; Cox-2 mRNA levels were determined using a coupled
reverse transcription–polymerase chain reaction (RT-PCR), per-
formed using a GeneAmp RNA PCR kit (Perkin-Elmer Corp)
according to the manufacturer’s instructions. To identify Cox-2
mRNA, exact primers were synthesized based on an analytical
RT-PCR procedure developed for human cyclooxygenase. The
Cox-2 primers were 59-TTCAAATGAGATTGTGGAAAAT-
TGCT-39 (27mer sense oligonucleotide at position 573) and 59-
AGATCATCTCTGCCTGAGTATCTT-39 (24mer antisense oligo-
nucleotide at position 878), resulting in a 305-bp PCR product.32
Primers were also synthesized to amplify the cDNA encoding
GAPDH, a constitutively expressed gene, as a control. The GAPDH
primers were 59-CCACCCATGGCAAATTCCATGGCA-39 (24mer
sense oligonucleotide at position 216) and 59-TCTAGACGGCAGG-
TCAGGTCCACC-39 (24mer antisense oligonucleotide at position
809), resulting in a 593-bp PCR product. RNA concentration was
determined spectrophotometrically; total cellular RNA samples from
each (1 mg) sample were reverse transcribed at 42°C for 30 minutes,
and the same amount of the resulting cDNA was used for amplifi-
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cation by specific primers for human Cox-2 and human GAPDH.
PCR amplification reaction was carried out in the presence of
0.2 mmol/L Cox-2 primers and 0.1 mmol/L GAPDH primers for 30
cycles with denaturation at 94°C for 1 minute, primer annealing at
55°C for 1 minute, and extension at 72°C for 1 minute, using a
thermal cycler GeneAmp PCR System 2400 (Perkin Elmer Corp).
Ten microliters of the amplified products was resolved by electro-
phoresis through a 2% agarose gel. Amplified cDNA bands were
detected by ethidium bromide staining.
Determination of Intracellular Lipids
Macrophage lipids were extracted with hexane/isopropanol (3:2,
vol/vol), 1 mL per well for 30 minutes, repeated twice. Extracts from
2 wells were pooled and total cholesterol and triglycerides were
quantified by enzymatic methods (Roche) and expressed as mg/mg of
cell protein.
Lipid Extraction From Native and Ox-LDL
Lipids were extracted from native and ox-LDL with chloroform/
methanol (2:1 vol/vol) containing 5 mg/mL butylated hydroxytolu-
ene.33 The organic phase was dried under nitrogen and the content of
extracts was determined by microgravimetry. The lipid residue was
dissolved in ethanol and added to culture medium. Total phospho-
lipids were isolated from the lipid extract by thin layer chromatog-
raphy on silica-gel 60 HR plates (Merck) using hexane/diethyl
ether/acetic acid (80:20:1 vol/vol/vol) as developing agents.34 After
brief exposure to iodine vapor, the zones containing total phospho-
lipids were scraped off, dissolved in chloroform, and added to culture
medium.
Vesicle Preparation
To prevent micellar formation, PC/lysoPC vesicles were prepared
using a 3:1 molar ratio of PC to lysoPC. A mixture of PC with 25
mol% of lysoPC was dissolved in chloroform and the solvent was
completely removed under a stream of nitrogen. The phospholipids
were dispersed in buffer (10 mmol/L Tris-HCl [pH 8.0], 150 mmol/L
NaCl, 0.01% EDTA, and 0.006% NaN3) containing 10 mg/mL
cholate. The vesicles were dialyzed twice in buffer and once in
saline.35
Neutral Lipid Staining
Macrophages were fixed with 4% formalin (pH 7.0) for 3 hours at
room temperature and stained for neutral lipids using a supersatu-
rated solution of Fat Red 7B in 70% ethanol. Hematoxylin was used
for nuclear staining, and stained cells were examined with phase
contrast microscopy.
Statistical Analysis
Data are reported as mean6SEM or as percentage of control for lipid
measurements. Statistical analyses were performed using a paired
Student’s t test.
Results
Effect of Bacterial Lipopolysaccharide on Cox-2
Protein Expression in Human Macrophages
Macrophages incubated with medium alone did not express
appreciable levels of Cox-2, whereas exposure to LPS (0.1 to
10 mg/mL) induced a concentration-dependent expression of
Cox-2 protein, recognized by a specific mAb as a doublet at
70 kDa. Timecourse experiments showed that the maximum
expression of the protein was reached within 4 hours and did
not change over 24 hours of incubation (data not shown). The
expression of protein detected 4 hours after LPS exposure
was accompanied by the formation of TXB2 from exogenous
arachidonate (0.6060.14 and 3.9461.1 ng/mL in unstimu-
lated and LPS-stimulated macrophages, respectively; n57;
P50.02).
Inhibition of Cox-2 Protein Synthesis by Ox-LDL
The exposure of unstimulated macrophages to medium for 24
hours did not induce Cox-2 expression, whereas stimulation
with LPS did induce Cox-2 expression (Figure 1). By
contrast, when macrophages were incubated with ox-LDL (50
mg/mL) for 2 to 24 hours, then stimulated with LPS for 4
hours, Cox-2 expression was completely inhibited (Figure 1).
Neither native nor otherwise-modified LDL influenced LPS-
induced Cox-2 expression (Figure 1). The inhibitory effect
exerted by ox-LDL was concentration-dependent: it was
appreciable at 25 mg/mL ox-LDL and was complete (.90%)
at 50 mg/mL (Figure 2A). The effect was selective for Cox-2;
levels of Cox-1 were unaffected (Figure 2B). The onset of the
inhibitory effect was rapid: inhibition was nearly 50% after 1
hour and was complete after 2 hours (Figure 3). Ox-LDL
reduced Cox-2 expression only when incubated with macro-
phages before the addition of LPS. Conversely, the incuba-
tion of cells with ox-LDL 1 hour after their exposure to LPS
did not affect Cox-2 levels (data not shown). As a conse-
quence of Cox-2 inhibition, a marked decrease of TXB2
Figure 1. Effect of native and modified LDL on LPS-induced
expression of Cox-2 protein in human macrophages. Macro-
phages were first incubated in medium alone or with 50 mg/mL
of native LDL, acetyl-LDL, ox-LDL, or MDA-LDL. LPS (1 mg/mL)
was then added for an additional 4 hours where indicated. For
Cox-2 and b-actin proteins, solubilized proteins of macrophages
were analyzed by Western blot using monoclonal Cox-2 and
b-actin antibodies. This figure is representative of 5
experiments.
Figure 2. (A) The inhibition of macrophage Cox-2 protein
expression by ox-LDL is concentration-dependent. Macro-
phages were first incubated in medium or with ox-LDL (6.25,
12.5, 25, and 50 mg/mL) then exposed to 1 mg/mL LPS where
indicated. (B) Same as (A), but using Cox-1 immunodetection.
For Cox-2, Cox-1, and b-actin proteins, solubilized proteins of
macrophages were analyzed by Western blot using monoclonal
Cox-2, Cox-1, and b-actin antibodies. This figure is representa-
tive of 2 to 4 experiments.
Eligini et al Oxidized LDL Inhibits Cox-2 1721
 by guest on October 7, 2012http://atvb.ahajournals.org/Downloaded from 
production from exogenous substrate was detected (3.9461.1
and 1.5160.47 ng/mL in LPS-treated cells and in LPS-treated
cells previously exposed to ox-LDL, respectively; n57;
P50.05).
Because ox-LDL is toxic to a variety of cells in culture,
cytotoxicity was measured to assess whether the inhibition of
Cox-2 was caused by cell death. Exposure of macrophages to
ox-LDL in concentrations up to 50 mg/mL for 24 hours did
not affect cell viability as assessed by Neutral Red assay.
The inhibition of Cox-2 protein expression by ox-LDL was
caused by attenuation of Cox-2 mRNA levels, as assessed by
RT-PCR analysis. The exposure of macrophages to 1 mg/mL
LPS for 1 hour was associated with Cox-2 mRNA accumu-
lation. Macrophage exposure to 50 mg/mL ox-LDL for 2
hours completely prevented the induction of Cox-2 mRNA by
LPS (Figure 4).
Uptake of Lipoproteins, Endocytosis and
Lysosomal Degradation Pathway
Native LDL did not affect intracellular total cholesterol,
whereas both ox-LDL and acetyl-LDL (50 mg/mL) increased
it to similar degrees; triglyceride levels were only marginally
affected (data not shown).
The uptake of ox- and acetyl-LDL was confirmed by Fat
Red staining. Human macrophages incubated for 24 hours
with ox-LDL adopted a foam cell–like morphology, with the
cytoplasm characterized by large accumulations of lipid
droplets that stained with Fat Red and were visible by light
microscopy (data not shown).
We next investigated whether the receptor-mediated endo-
cytosis was a prerequisite for the inhibitory effect of ox-LDL
on Cox-2. Cells were preincubated for 15 minutes with
fucoidin (30 mg/mL), a specific ligand for the scavenger
receptor, or with cytochalasin B (1 to 5 mg/mL), which blocks
endocytosis. Ox-LDL (50 mg/mL) was added in the presence
of fucoidin or cytochalasin B for an additional 24 hours. The
medium was removed and macrophages were exposed to LPS
for 4 hours. The data indicate that the inhibitory effect of
ox-LDL on Cox-2 induced by LPS was not prevented by the
binding of the scavenger receptor (Figure 5). In contrast, the
inhibition of endocytosis exerted by cytochalasin B resulted
in the recovery of Cox-2 induced by LPS (Figure 5).
To assess whether the degradation pathway of endocytosed
ox-LDL was relevant to the inhibition exerted on Cox-2,
chloroquine (50 mmol/L), an inhibitor of lysosomal acid
hydrolases, was added to culture medium containing ox-LDL.
The effect of ox-LDL on Cox-2 was not changed by chloro-
quine (data not shown). These data suggest that the incorpo-
ration of ox-LDL particle by macrophages, but not its
degradation, is a prerequisite for the inhibitory effect on
Cox-2.
Localization of the Inhibitory Component to the
Lipid Fraction of Ox-LDL
To examine whether the inhibitory activity of ox-LDL was
associated with the lipid component of the particle, we
incubated macrophages with chloroform-methanol extracts of
native and ox-LDL (equivalent to 25 to 50 mg LDL pro-
tein/mL of culture medium) before stimulation with LPS. The
lipid extracts from ox-LDL inhibited the enzyme synthesis
induced by LPS, whereas those from native LDL did not
(Figure 6).
A number of oxidized lipid compounds (lysoPC, 7-oxocho-
lesterol, and 7b-hydroxy-cholesterol), all identified in ox-
LDL36,37 as well as in atherosclerotic plaques,3,38 were tested
for their ability to influence Cox-2 at concentrations close to
that reported to possess biological activity.5,39,40 LysoPC (25
to 50 mg/mL), 7-oxocholesterol (5 mg/mL), and 7b-hydroxy-
cholesterol (5 mg/mL) did not affect the expression of Cox-2
when added to culture medium up to 24 hours before
macrophage exposure to LPS (data not shown).
Macrophages were then exposed to the phospholipid frac-
tions isolated from native and ox-LDL (at levels equivalent to
50 mg LDL protein/mL of culture medium). Phospholipids
extracted from ox-LDL, but not those extracted from native
Figure 3. Onset of Cox-2 inhibition by ox-LDL in human macro-
phages. Macrophages were first incubated with medium alone
or with 50 mg/mL ox-LDL for 1 and 2 hours. LPS (1 mg/mL) was
then added where indicated. This figure is representative of 3
experiments.
Figure 4. RT-PCR analysis of mRNA for Cox-2 in human mac-
rophages exposed to ox-LDL. Macrophages were first incu-
bated for 2 hours in medium alone or with 50 mg/mL ox-LDL.
Medium alone or LPS (1 mg/mL) was then added for an addi-
tional hour. Total cellular RNA was extracted and Cox-2 and
GAPDH mRNA levels were estimated by RT-PCR. GAPDH
mRNA was used as an internal standard. The sequences of the
primer sets and oligonucleotide probes for Cox-2 and GAPDH
mRNA are shown in the Methods. This figure is representative
of 2 experiments.
Figure 5. Endocytosis, but not binding to scavenger receptors,
is a prerequisite for the inhibition of Cox-2 expression by
ox-LDL. Macrophages were first incubated in medium only, 50
mg/mL ox-LDL, 30 mg/mL fucoidin plus 50 mg/mL ox-LDL, or 5
mg/mL cytochalasin B plus 50 mg/mL ox-LDL. LPS (1 mg/mL)
was added where indicated. Western blotting was performed as
for Figure 1. This figure is representative of 3 experiments.
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LDL, fully mimicked the inhibition of Cox-2 exerted by
intact ox-LDL (Figure 7).
Among phospholipids generated during oxidative modifica-
tion of LDL, Ox-PAPC, a mixture of oxidized arachidonic
acid–containing phospholipids that is obtained by autoxidation
of 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine,
has been reported to be responsible for some biological activities
of ox-LDL that are relevant in atherogenesis.41 In addition, the
evidence for the importance of these compounds in vivo is
suggested by their presence in fatty streak lesions from choles-
terol-fed rabbits.29 Ox-PAPC, incubated for 2 hours with mac-
rophages at 5 mg/mL, a concentration reported to be present in
50 mg/mL ox-LDL,41 completely abolished the LPS induction of
Cox-2, comparable to the effect exerted by ox-LDL in toto
(Figure 8). PAPC in its nonoxidized form had no effect on Cox-2
(Figure 8), and reduction of ox-PAPC with sodium borohydride
abolished the capacity of ox-PAPC to inhibit Cox-2 (Figure 8).
Discussion
The data presented in this study indicate that ox-LDL, but not
native or other modified forms of LDL (acetyl-LDL, MDA-
LDL), at concentrations that are not cytotoxic, markedly
inhibits Cox-2 protein and mRNA induced by LPS in human
macrophages. The inhibitory effect of ox-LDL on Cox-2 was
not mediated by intracellular cholesterol accumulation: cho-
lesterol levels in macrophages exposed to ox-LDL were
similar to those obtained with acetyl-LDL, which does not
inhibit Cox-2. Preincubation of macrophages with fucoidin
for 24 hours did not affect the inhibition by ox-LDL,
suggesting that the recognition of the scavenger receptor by
ox-LDL is not responsible for Cox-2 inhibition, at least in
experimental conditions in which macrophages are exposed
to ox-LDL for a relatively long time period. Moreover,
macrophages possess several structures that function as scav-
enger receptors not only for modified lipoproteins but also for
anionic phospholipids.42,43 Thus, the interaction of ox-LDL
with other novel classes of receptors may account for Cox-2
inhibition. Interestingly, Cox-2 was inhibited when macro-
phages were exposed to the lipid extract of ox-LDL. Among
the lipid constituents that have been found in ox-LDL,
lysoPC, 7-oxocholesterol, and 7b-hydroxy-cholesterol failed
to mimic the inhibition of Cox-2 exerted by ox-LDL. In
contrast, ox-PAPC, a surrogate mixture of oxidized arachi-
donic acid–containing phospholipids, abolished Cox-2 ex-
pression. Ox-PAPC (obtained by autoxidation of 1-palmitoyl-
2-arachidonoyl-sn-glycero-3-phosphocholine) is a mixture of
products, some of which have been identified in mildly
oxidized-LDL,41 and is considered to be responsible for the
biological activity of mildly oxidized-LDL.41 Two of these
compounds have been further characterized in terms of
molecular structure and biological activity.29 In addition, the
presence of these oxidized phospholipids in fatty streak
lesions from cholesterol-fed rabbits has been documented,29
which suggests that specific oxidized derivatives of arachi-
donic acid–containing phospholipids may be important initi-
ators of atherogenesis. Interestingly, the hypothesis that
phospholipids generated during oxidative modification of
LDL may participate in atherosclerosis is supported by their
biological activities, eg, the capacity to stimulate smooth
muscle cell proliferation and to induce leukocyte activation.44
Oxidative modification of PAPC was essential for the
inhibitory effect on Cox-2 because it was observed neither
with the unoxidized mixture nor after reduction of ox-PAPC.
The finding that the phospholipid fraction extracted from
ox-LDL, but not that from native LDL, inhibits Cox-2 in a
fashion fully comparable to that exerted by ox-LDL in toto
indicates that a component(s) responsible for the impairment
of Cox-2 is localized to the phospholipid fraction of ox-LDL,
probably the arachidonic acid–containing phospholipids.
The observation that ox-LDL downregulates Cox-2 in
human macrophages consistent with a number of re-
ports23,24,45–48 dealing with a suppressive effect of ox-LDL on
inducible inflammatory genes in macrophages: in particular,
inhibition of cytokine gene mRNAs as well as of inducible
nitric oxide synthase and platelet-derived growth factor
Figure 6. The inhibitory activity of ox-LDL is associated with the
lipid component of the lipoprotein. Macrophages were first incu-
bated with medium or with lipid extracts equivalent to 25 and
50 mg LDL protein/mL from ox-LDL and native LDL. The effect
of lipid extracts was compared with that of 50 mg/mL ox-LDL.
Cells were subsequently exposed to 1 mg/mL LPS. Western
blotting was performed as for Figure 1. This figure is represen-
tative of 3 experiments.
Figure 7. Phospholipids (PLs) extracted from ox-LDL but not
those extracted from native LDL mimic the inhibitory effect of
ox-LDL on Cox-2. Macrophages were exposed to medium or to
the PL fraction isolated from ox-LDL and native LDL at levels
equivalent to 50 mg LDL protein/mL of culture medium. The
effect of PL extracts was compared with that of 50 mg/mL
ox-LDL. LPS (1 mg/mL) was then added where indicated. West-
ern blotting was performed as for Figure 1. This figure is repre-
sentative of 2 experiments.
Figure 8. PAPC (1-palmitoyl-2-arachidonoyl-sn-glycero-3-
phosphocholine), a surrogate arachidonic acid–containing phos-
pholipid, abolishes Cox-2 in its oxidized form only. Macro-
phages were first incubated with medium or with 5 mg/mL
PAPC in its unoxidized form, its oxidized form (ox-PAPC), or its
oxidized-reduced form (ox-PAPC reduced). The effect of
ox-PAPC was compared with that of 50 mg/mL ox-LDL. LPS (1
mg/mL) was then added where indicated. Western blotting was
performed as for Figure 1. This figure is representative of 5
experiments.
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B-chain. Thus it is clear that ox-LDL impairs the response of
macrophages to inflammatory stimuli. Interestingly, in ather-
oma the magnitude of cytokine expression is diminished or
lacking in regions proximal to the lesion core, where macro-
phages may accumulate greater amounts of oxidized lipids or
may have been exposed to LDL that has been more exten-
sively oxidized.24
Our data indicate that in macrophages exposed to ox-LDL
the synthesis of eicosanoids is also impaired. Besides having
a role in the inflammatory response, eicosanoids, in particular
prostaglandin E2 and prostacyclin, negatively affect release of
macrophage colony stimulating factor (M-CSF) by mono-
cytes49,50 and by various cell types within the atheroma.51
Considering the role of M-CSF in atherogenesis,52 one could
envision that ox-LDL, through the inhibition of eicosanoid
synthesis, markedly enhances M-CSF availability within the
atheroma. This condition, which favors macrophage prolifer-
ation and accumulation, ultimately accelerates the progres-
sion of atherogenesis.
The observation of a marked reduction of Cox-2 mRNA
levels in LPS-stimulated macrophages exposed to ox-LDL
suggests that ox-LDL affects either Cox-2 mRNA stabiliza-
tion/degradation or that it operates at transcriptional level.
Previous reports have found that ox-LDL inhibits selected
genes and functions of macrophages through this latter
mechanism: ox-LDL inhibits LPS-induced binding of the
transcription factors NF-kB and AP-1 to DNA.40,53,54 These
transcription factors are involved in the regulation of several
genes induced in macrophages by inflammatory stimuli such
as LPS,55,56 and recently, the requirement of the activation of
NF-kB to induce the expression of Cox-2 in LPS-stimulated
macrophages has been described.20
In conclusion, we showed that Cox-2 expression induced
by LPS is suppressed by ox-LDL in human macrophages.
This finding represents a further demonstration of a link
between the oxidative modification of LDL and the dampen-
ing of the inflammatory potential of macrophages. The
observed effect could be relevant in atheromata, where close
contact between macrophages and oxidized lipids might
ultimately result in the development of an impaired inflam-
matory response, together with a cell failure to repair tissue
damage. This phenomenon may thus represent an important
contributing feature in the conversion of the early atheroscle-
rotic lesion to a late, less reversible lesion.
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